Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists

F. Ivy Carroll; S. Mascarella; Hernan A. Navarro; James B. Thomas; Scott P. Runyon; Pauline Wanjiku Ondachi; Chad Michael Kormos; Ivy Carroll; Chad Michael Kormos; Pauline Wanjiku Ondachi; Scott P. Runyon; Hernan A. Navarro; James B. Thomas; S. Wayne Mascarella

Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists

Carroll, I., Kormos, C. M., Ondachi, P. W., Runyon, S. P., Navarro, H. A., Thomas, J. B., & Mascarella, S. W. (2022). Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists. (U.S. Patent No. 11,292,783). U.S. Patent & Trademark Office, Washington, DC. https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&

Copy citation

Abstract

Potent opioid receptor antagonists of formula (I) and their use as pharmacotherapies for treating depression, anxiety, schizophrenia, eating disorders, and addiction to cocaine, methamphetamine, nicotine, alcohol, and opiates are disclosed. More specifically, the disclosure provides potent and selective kappa opioid receptor antagonist compounds, pharmaceutical compositions of those compounds and uses of those compounds to ameliorate or treat addictions, eating disorders, etc. ##STR00001##